Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dendreon’s Story Of Continuing Slow Growth For Provenge Seems Unconvincing To Wall Street

This article was originally published in The Pink Sheet Daily

Executive Summary

Dendreon’s new CEO has yet to articulate whether he plans large-scale strategic changes to how the company markets Provenge, instead focusing his early comments to investors on deeper penetration of existing accounts and guiding to low-single-digit quarterly sales growth.

You may also be interested in...

Opening A Window: Algeta Must Find Xofigo’s Place In The Prostate Cancer Market

Bayer/Algeta’s Xofigo was cleared for castration-resistant prostate cancer patients with symptomatic bone metastases, but uptake of the radiotherapeutic will require referrals from most providers to a licensed radiation site and the company must find a way for the drug to be used instead of or in sequence with chemo and other prostate cancer therapies.

A New Chapter, A New CEO For Dendreon

Former Savient and ImClone CEO Johnson will be responsible for driving commercial expansion of Provenge in the U.S. and Europe. Mitchell Gold steps down as CEO after successfully getting the prostate cancer drug to market following an arduous FDA review but struggling with commercial complexities.

Dendreon Rebounds In Q4 2011, But Can It Keep It Up In 2012?

The biotech reported gross product revenue for Provenge of approximately $82 million in Q4 2011, better than doubling Q4 2010 sales. Management credits improved reimbursement dynamics and sales execution.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts